丙肝治疗直接抗病毒药物价格分析

Price analyses on direct-acting antiviral drugs of hepatitis C

全口服直接抗病毒药物(DAA)的上市为消除丙肝带来巨大机遇。本文通过梳理世界卫生组织近年更新的关于丙肝治疗的指南建议,并分析DAA药品的市场动态、价格趋势以及全球治疗进展,探讨目前DAA药物价格情况,治疗的可及性及其影响因素。结果显示WHO推荐使用DAA进行治疗,但DAA的价格昂贵,虽然各国采取措施降低价格,提高可及性,但DAA治疗的推进却不尽如人意,覆盖面依然不高。除了价格以外,还需考虑策略、卫生系统、可及性和服务提供等因素,采用公共卫生方法,推进DAA治疗,以实现丙肝的消除。

The oral direct-acting antiviral drug(DAA)offers tremendous opportunities to eliminate hepatitis C.We analyzed the market trends,price trends and global treatment progress of DAA drugs by reviewing the guidelines recommended by the World Health Organization for the treatment of hepatitis C,and discusses the current accessibility of DAA treatment and its influencing factors.The results show that WHO recommends the use of DAA for treatment of hepatitis C,but the price of DAA is expensive.Although some countries have taken measures to lower prices and improve accessibility,the advancement of DAA treatment has been unsatisfactory and coverage is still not high.In addition to price,factors such as strategy,health system,accessibility and service provision need to be considered,and public health methods should be adopted to promote DAA treatment to achieve the elimination of hepatitis C.